According to study results presented at the 2024 American Urological Association Annual Meeting, immune checkpoint inhibitors (ICIs), a type of immunotherapy (IO), significantly improve survival for patients with metastatic renal cell carcinoma (mRCC) and sarcomatoid features who undergo cytoreductive nephrectomy (CN), regardless of the timing of surgery. ...
Advanced Renal Cell Carcinoma
Advertisement
Latest News
Researchers completed a comprehensive evaluation of features that can serve as biomarkers of response to ICB therapy in mRCC.
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
Dr. Swami investigated the efficacy of cabozantinib in combination with immune checkpoint inhibitors for mccRCC.
Dr. Zakharia continues his commentary on the BTCRC-GU16-043 study investigating guadecitabine and durvalumab in accRCC.
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Advertisement
Section Editor
Katy Beckermann, MD, PhDGenitourinary Medical Oncologist | Vanderbilt-Ingram Cancer Center
Advertisement
Get the latest RCC research straight to your inbox.
